Kabra Drugs

Why is Kabra Drugs Ltd falling/rising?

As of 11-Aug, Kabra Drugs Ltd's stock price is at 23.68, reflecting a decline of 1.21% and a significant year-to-date drop of 22.49%. The stock is underperforming its sector and experiencing decreased investor interest, contributing to its ongoing downward trend.

As of 11-Aug, Kabra Drugs Ltd's stock price is falling, currently at 23.68, which reflects a decrease of 0.29 or 1.21%. The stock has been underperforming, having lost 2.84% over the last two days, marking a consecutive decline. Additionally, the stock's performance today has underperformed its sector by 2.21%. <BR><BR>In terms of broader performance metrics, the stock has seen a significant decline of 22.49% year-to-date, contrasting with a smaller decline of 8.29% in the Sensex. Although the stock has shown a positive return of 9.12% over the past month, this short-term gain does not offset the longer-term downward trend. <BR><BR>Investor participation is also declining, as evidenced by a 19.03% drop in delivery volume compared to the 5-day average. This reduction in trading activity indicates a lack of interest among investors, which can contribute to the stock's falling price. Furthermore, while the stock is trading above its 20-day and 50-day moving averages, it is below its 5-day, 100-day, and 200-day moving averages, suggesting a bearish trend in the short to medium term. Overall, these factors collectively explain the current decline in Kabra Drugs Ltd's stock price.

Which are the latest news on Kabra Drugs?

When is the next results date for Kabra Drugs Ltd?

Kabra Drugs Ltd will announce its results on 12 August 2026.

Kabra Drugs Ltd will declare its results on 12 August 2026.

Should I buy, sell or hold Kabra Drugs Ltd?

How big is Kabra Drugs?

As of 10th June, Kabra Drugs Ltd has a market capitalization of 52.00 Cr, with recent net sales of 92.74 Cr and a net profit of 4.97 Cr. Shareholder's funds are 24.65 Cr, and total assets amount to 25.23 Cr as of March 2025.

As of 10th June, Kabra Drugs Ltd has a market capitalization of 52.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Kabra Drugs reported Net Sales of 92.74 Cr and a Net Profit of 4.97 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 24.65 Cr and Total Assets of 25.23 Cr.

Who are in the management team of Kabra Drugs?

The management team of Kabra Drugs includes B V Anatha Kumar (Whole Time Director & CFO), R Muralidharan, Ananthkumar Shilpa, Churchil Durai M Jebastine (all Independent Directors), Nidhi Bhaskar and Monika Sanwal (Company Secretaries), and A Anitha and KUNIAMUTHUR NANJAPPAN ANAND (Additional Directors).

The management team of Kabra Drugs includes the following individuals:<BR><BR>1. B V Anatha Kumar - Whole Time Director & CFO<BR>2. R Muralidharan - Independent Director<BR>3. Ananthkumar Shilpa - Independent Director<BR>4. Churchil Durai M Jebastine - Independent Director<BR>5. Nidhi Bhaskar - Company Secretary<BR>6. KUNIAMUTHUR NANJAPPAN ANAND - Additional Director<BR>7. Monika Sanwal - Company Secretary & Compliance Officer<BR>8. A Anitha - Additional Director<BR><BR>If you need more information about their roles or the company, feel free to ask!

Who are the peers of the Kabra Drugs?

Kabra Drugs' peers include Biofil Chemicals, Asston Pharmaceu, Vivo Bio Tech, Shelter Pharma, Veerhealth Care, Vasundhara Rasy., Mangalam Drugs, Rajnish Wellness, and Vista Pharma. Kabra Drugs shows excellent growth and a 1-year return of 86.81%, outperforming its peers significantly.

Peers: The peers of Kabra Drugs are Biofil Chemicals, Asston Pharmaceu, Vivo Bio Tech, Shelter Pharma, Veerhealth Care, Vasundhara Rasy., Mangalam Drugs, Rajnish Wellness, and Vista Pharma.<BR><BR>Quality Snapshot: Below Average management risk is observed at Biofil Chemicals, Kabra Drugs, Vivo Bio Tech, Veerhealth Care, Mangalam Drugs, and Vista Pharma, while Average management risk is found at Asston Pharmaceu, Shelter Pharma, and Rajnish Wellness, and Good management risk is noted at Vasundhara Rasy. Growth is Excellent at Kabra Drugs, Good at Shelter Pharma, Average at Veerhealth Care, and Below Average at Biofil Chemicals, Asston Pharmaceu, Vivo Bio Tech, Mangalam Drugs, Rajnish Wellness, and Vista Pharma. Capital Structure is Good at Biofil Chemicals, Veerhealth Care, and Vasundhara Rasy., Average at Asston Pharmaceu and Shelter Pharma, and Below Average at Kabra Drugs, Vivo Bio Tech, Mangalam Drugs, Rajnish Wellness, and Vista Pharma.<BR><BR>Return Snapshot: Kabra Drugs has a 1-year return of 86.81%, which is significantly higher than the peer with the highest return, Veerhealth Care at 39.82%, and the peer with the lowest return, Mangalam Drugs at -65.43%. Additionally, the six-month returns for Biofil Chemicals, Vivo Bio Tech, Shelter Pharma, Mangalam Drugs, Rajnish Wellness, and Vista Pharma are all negative.

What does Kabra Drugs do?

Kabra Drugs Ltd is a Micro Cap manufacturer of Ether derivatives in the Pharmaceuticals & Biotechnology industry, with net sales of 35 Cr and a net profit of 1 Cr for the quarter ending March 2026. The company has a market cap of INR 52 Cr and key metrics include a P/E ratio of 10.00 and a return on equity of 19.08%.

Overview:<BR>Kabra Drugs Ltd is a manufacturer of Ether derivatives in the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>History:<BR>Kabra Drugs Limited was incorporated as a Limited Company on August 22, 1989. The company commenced commercial production in 1991 and has reported net sales and profit for the quarter ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 35 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 1 Cr (Quarterly Results - Mar 2026)<BR>- Market cap: INR 52 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 10.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.43<BR>- Return on Equity: 19.08%<BR>- Price to Book: 1.98<BR><BR>Contact Details:<BR>Address: 270 Shastri Market Indore, Indore Madhya Pradesh: 452007<BR>Email: kabradrugs@rediffmail.com<BR>Website: http://www.kabradrugslimited.com

How has been the historical performance of Kabra Drugs?

Kabra Drugs has consistently generated no significant revenue from March 2021 to March 2025, with increasing operating losses reaching -1.08 Cr by March 2025, despite an improvement in shareholder's funds to 24.65 Cr due to increased equity capital. Total liabilities rose to 25.23 Cr, while financing activities resulted in a net cash inflow of 18.00 Cr.

Answer:<BR>The historical performance of Kabra Drugs shows a consistent lack of revenue generation, with net sales remaining at zero from March 2021 to March 2025, except for a nominal figure of 0.01 Cr in March 2019. The total operating income also reflects this trend, with minimal other operating income recorded in previous years. The company has incurred increasing total expenditures, rising from 0.05 Cr in March 2020 to 1.72 Cr in March 2025, primarily driven by employee costs and other expenses. Operating profit has been negative throughout this period, with losses deepening from -0.13 Cr in March 2019 to -1.08 Cr in March 2025. The profit before tax and profit after tax figures mirror this decline, showing losses that have increased over the years. On the balance sheet, shareholder's funds improved from -0.73 Cr in March 2023 to 24.65 Cr in March 2025, largely due to an increase in equity capital. Total liabilities rose significantly to 25.23 Cr in March 2025, while total assets also increased to the same amount, indicating a growing but unprofitable operation. Cash flow from operating activities has been negative, with a notable cash inflow from financing activities in March 2025, resulting in a net cash inflow of 18.00 Cr.<BR><BR>Breakdown:<BR>Kabra Drugs has not generated any significant revenue over the years, with net sales consistently at zero from March 2021 to March 2025, except for a slight revenue in March 2019. The total operating income has remained low, with only minor other operating income recorded in earlier years. Total expenditures have escalated, particularly in employee costs and other expenses, leading to increasing operating losses, which reached -1.08 Cr by March 2025. The company's financial position has seen a notable improvement in shareholder's funds, which rose to 24.65 Cr in March 2025, driven by a substantial increase in equity capital. However, total liabilities also surged to 25.23 Cr, reflecting the company's growing financial obligations. Despite these challenges, cash flow from financing activities provided a significant boost, resulting in a net cash inflow of 18.00 Cr in March 2025, although cash flow from operating activities remained negative.

Are Kabra Drugs latest results good or bad?

Kabra Drugs' latest results show flat net sales but a significant 228.21% decline in standalone net profit, prompting MarketsMOJO to issue a 'Sell' recommendation. Investors should be cautious due to concerns about the company's profitability in a competitive market.

Kabra Drugs' latest results for the quarter ending June 2025 indicate a flat financial performance, with no significant changes in net sales compared to the previous quarter. However, the company has experienced a notable decline in standalone net profit, which dropped by 228.21% from the previous quarter, reflecting a challenging situation. <BR><BR>Given this performance, MarketsMOJO has issued a 'Sell' call on the stock, suggesting that investors should approach with caution. Overall, while the company shows stability in some metrics, the significant drop in profitability raises concerns about its current trajectory in the competitive pharmaceuticals and biotechnology sector. Investors will likely be looking for further developments in the upcoming quarters to better assess the company's future prospects.

Who are the top shareholders of the Kabra Drugs?

The top shareholders of Kabra Drugs are primarily individual investors, holding 96.19% of the shares, with Kuniamuthur Nanjappan Anand being the largest public shareholder at 6.53%. There are no institutional investors or pledged promoter holdings.

The top shareholders of Kabra Drugs primarily consist of individual investors, who hold a significant 96.19% of the company's shares. Among public shareholders, Kuniamuthur Nanjappan Anand stands out with a holding of 6.53%. There are no institutional investors or mutual funds currently holding shares in the company, and there are no pledged promoter holdings. Overall, the majority of the ownership is concentrated in the hands of individual investors.

Is Kabra Drugs overvalued or undervalued?

As of November 12, 2024, Kabra Drugs is rated as risky and overvalued, with negative financial ratios compared to competitors like Sun Pharma and Cipla, despite a recent short-term stock performance that outpaced the Sensex.

As of 12 November 2024, the valuation grade for Kabra Drugs has moved from does not qualify to risky, indicating a significant shift in its financial standing. The company is currently assessed as overvalued, with a PE ratio of -27.57, an EV to EBITDA ratio of -28.95, and a ROCE of -33.00%. These negative ratios suggest that the company is facing substantial financial challenges compared to its peers.<BR><BR>In comparison to notable competitors, Kabra Drugs' valuation stands out unfavorably. For instance, Sun Pharma has a PE ratio of 35.25, while Cipla boasts a PE of 22.99, both indicating a much healthier valuation environment in the industry. The stark contrast in these ratios highlights the overvaluation of Kabra Drugs. Additionally, the company's recent stock performance has outpaced the Sensex over the past week, returning 4.99% compared to the Sensex's 1.45%, but this short-term gain does not mitigate the overall valuation concerns reflected in its financial ratios.

What is the technical trend for Kabra Drugs?

As of May 27, 2025, Kabra Drugs shows a mildly bullish trend, supported by positive MACD and RSI indicators, although caution is advised due to a mildly bearish KST on the weekly chart.

As of 27 May 2025, the technical trend for Kabra Drugs has changed from bullish to mildly bullish. The weekly MACD and RSI are both bullish, indicating positive momentum in the short term. The daily moving averages also reflect a bullish stance. However, the KST on a weekly basis is mildly bearish, suggesting some caution. The Bollinger Bands show a mildly bullish trend on the weekly chart while remaining bullish on the monthly chart. Dow Theory indicates no trend on the weekly but is mildly bullish on the monthly. Overall, the current technical stance is mildly bullish, driven primarily by the strong performance in MACD and RSI across multiple time frames.